Carmichael Hill & Associates’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Carmichael Hill & Associates’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$233	Sell	62 -1	-2%	-$6	﹤0.01%	759
2024 Q2	$597	Hold	63	–	–	﹤0.01%	744
2024 Q1	$4.73K	Buy	63 +24	+62%	+$3.17K	﹤0.01%	638
2023 Q4	$6.95K	Buy	39 +31	+388%	+$15.3K	﹤0.01%	622
2023 Q3	$5.7K	Buy	8 +3	+60%	+$12.9K	﹤0.01%	627
2023 Q2	$25.1K	Hold	5	–	–	0.01%	437
2023 Q1	$14.5K	Buy	5 +2	+67%	+$5.86K	0.01%	497
2022 Q4	$7.47K	Hold	3	–	–	﹤0.01%	588
2022 Q3	$11K	Buy	3 +1	+50%	+$3.93K	0.01%	554
2022 Q2	$6K	Hold	2	–	–	﹤0.01%	642
2022 Q1	$5K	Buy	2 +1	+100%	+$4.3K	﹤0.01%	694
2021 Q4	$6K	Hold	1	–	–	﹤0.01%	696
2021 Q3	$5K	Buy	+1	New	+$8.59K	﹤0.01%	701

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

Carmichael Hill & Associates's SEEL Position: Q3 2024 in Review

Carmichael Hill & Associates reduced its Seelos Therapeutics, Inc. Common Stock (SEEL) stake by 1.6% in Q3 2024, selling an estimated $6 and leaving 62 shares worth $233. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Carmichael Hill & Associates first reported a position in SEEL in Q3 2021 and has held it in 13 quarters since. The position peaked at $25.1K in Q2 2023. 15 funds tracked by Wall St. Rank hold SEEL as of Q3 2024.

Carmichael Hill & Associates held 62 shares of Seelos Therapeutics, Inc. Common Stock worth $233 as of Q3 2024.
Carmichael Hill & Associates sold 1 Seelos Therapeutics, Inc. Common Stock share in Q3 2024, an estimated $6.
Seelos Therapeutics, Inc. Common Stock made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #759 holding.
Carmichael Hill & Associates first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and has held it in 13 quarters since.
Carmichael Hill & Associates's Seelos Therapeutics, Inc. Common Stock position peaked at $25.1K in Q2 2023.
15 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.